RepГєblica Oriental del Uruguay with offices at Francisco GarcГa Cortinas 2357, Piso 1, CP 11.300, Montevideo, Uruguay Phone: (54-11) 4775-8544 Fax: (54-11) 4803-2505 Australia Regional Technology Systems Pty Ltd 3-11 Primrose Avenue Rosebery, New South Wales, 2018, Australia Phone: 1300 659 281 Bulgaria Vegamedical Bulgaria Blvd. Weksler is also attending physician at NewYork-Presbyterian/Weill Cornell.вЂ‹ Argentina & Uruguay DeLeC Cientifica Uruguaya S.A. Weksler is the Irving Sherwood Wright Professor of Geriatrics and professor of medicine at Weill Medical College of Cornell University in New York City. It is possible that the wide repertoire of anti-amyloid antibodies present in IVIg as well as other effects on the immune system contribute to the clinical benefits.'Дr. Marc Weksler, the study's co-principal investigator, observes that 'IVIg's potent effects on beta amyloid levels in spinal fluid are certainly remarkable given the modest levels of anti-amyloid antibodies it contains. 'The persisting clinical benefits we see as IVIg decreases spinal fluid amyloid levels suggests that beta amyloid is the right target for the next generation of Alzheimer treatments,' says Dr. On average, spinal fluid beta amyloid levels were reduced by about a third, consistent with mobilization of amyloid out of the central nervous system and into the blood stream where it is cleared from the body. In the NewYork-Presbyterian/Weill Cornell clinical study, IVIg administration transiently altered levels of the beta amyloid ?peptide in blood and caused a lasting decrease in beta amyloid levels in spinal fluid. Norman Relkin, director of the Memory Disorders Program at NewYork-Presbyterian/Weill Cornell and associate professor of clinical neurology and neuroscience at Weill Medical College of Cornell University. The study's principal investigator is Dr. Without treatment, AD is relentlessly progressive and usually causes measurable decline in thinking abilities over a comparable period of months. 'The majority of the Alzheimer patients in our study remained at or above their baseline level of cognitive performance18 months after they first received IVIg,' according to Basia Adamiak, who coordinated the IVIg open-label extension study at NewYork-Presbyterian/Weill Cornell. Six of the eight patients benefited clinically from the resumption of IVIg.

IVIg was given every other week and was well-tolerated by all eight patients. Investigators decided to resume IVIg at a low dose in a nine-month open-label extension study. These patients subsequently declined when IVIg was stopped for three months. In a previously reported six-month pilot study, the NewYork-Presbyterian/Weill Cornell team found that IVIg administration improved or stabilized the cognitive test scores of eight patients with mild to moderate AD.

It has only recently been studied for the treatment of Alzheimer's. It has been safely used in hundreds of thousands of patients. FDA-approved for treating several immune disorders, IVIg has been available for more than 30 years.

It is believed that IVIg helps promote the clearance of AВ§ from the brain and block AВ§'s toxic effects on brain cells. IVIg contains antibodies that bind to beta amyloid (AВ§), a central component of the plaque in the brains of Alzheimer's patients.

Results were announced at the International Conference on Alzheimer's Disease and Related Disorders (ICAD) in Madrid today. The clinical study is the first to demonstrate that IVIg stabilizes or improves cognitive function in Alzheimer patients when administered over a period of a year or more. NEW YORK (July 24, 2006) - A purified mixture of human antibodies called intravenous immunoglobulin (IVIg) provides lasting benefits to patients with Alzheimer's disease (AD), according to researchers at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

Icad madrid